Successful treatment result after 3 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 3 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 3 months after start of the study intervention.
Successful treatment result after 6 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 6 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 6 months after start of the study intervention.
Successful treatment result after 24 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 24 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 24 months after start of the study intervention.
Boston Carpal Tunnel Questionnaire Symptom Severity Scale
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (range 1-5)
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Boston Carpal Tunnel Questionnaire Functional Status Scale
Boston Carpal Tunnel Questionnaire Functional Status Scale (range 1-5)
Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ FSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related functional impairment. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Nerve conduction studies: Motor median nerve distal latency
Nerve conduction studies of motor median nerve distal latency (milliseconds)
Measurement points:
Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis.
Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve proximal latency
Nerve conduction studies of motor median nerve proximal latency (milliseconds)
Median nerve measurement points:
Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis.
Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve amplitude
Nerve conduction studies of motor median nerve amplitude (millivolts)
Median nerve measurement points:
Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis.
Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve conduction velocity
Nerve conduction studies of motor median nerve amplitude conduction velocity (meters per second)
Median nerve measurement points:
Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis.
Proximal: at the cubital fossa
Nerve conduction studies: Motor ulnar nerve distal latency
Nerve conduction studies of motor ulnar nerve distal latency (milliseconds)
Ulnar nerve measurement points:
Distal: at the wrist, 8 cm proximal to the abductor digiti minimi
Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve proximal latency
Nerve conduction studies of motor ulnar nerve proximal latency (milliseconds)
Ulnar nerve measurement points:
Distal: at the wrist, 8 cm proximal to the abductor digiti minimi
Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve amplitude
Nerve conduction studies of motor ulnar nerve amplitude (millivolts)
Ulnar nerve measurement points:
Distal: at the wrist, 8 cm proximal to the abductor digiti minimi
Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve conduction velocity
Nerve conduction studies of motor ulnar nerve conduction velocity (meters per second)
Ulnar nerve measurement points:
Distal: at the wrist, 8 cm proximal to the abductor digiti minimi
Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Sensory median nerve latency
Nerve conduction studies of sensory median nerve latency (milliseconds)
Median nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory median nerve amplitude
Nerve conduction studies of sensory median nerve amplitude (microvolts)
Median nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory median nerve conduction velocity
Nerve conduction studies of sensory median nerve conduction velocity (meters per second)
Median nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve latency
Nerve conduction studies of sensory ulnar nerve latency (milliseconds)
Ulnar nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve amplitude
Nerve conduction studies of sensory ulnar nerve amplitude (microvolts)
Ulnar nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve conduction velocity
Nerve conduction studies of sensory ulnar nerve conduction velocity (meters per second)
Ulnar nerve measurement points:
Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Electromyography: Spontaneous activity
Electromyography recording spontaneous activity in m.abductor pollicis brevis (Yes/No)
Electromyography: Chronic neurogenic changes
Electromyography recording chronic neurogenic changes in m.abductor pollicis brevis (Yes/No)
Nerve conduction studies: Bland score
Scoring of motor and sensory nerve conduction studies using the Bland scoring system (Bland, et al. 2000):
0: normal
1: very mild
2: mild
3: moderate
4: severe
5: very severe
6: extremely severe
7: not gradable
Semmes-Weinstein monofilament test
Bilateral test of sensory function in digits 1,2 and 5 using a 2.83 monofilament. Graded absent/present.
Grip strength
Test of grip strength using dynamometer. Range 0-90 kg.
Grip ability test (GAT)
Simplified version of the Sollerman grip function test. Measures time for subject to perform 3 tasks: Pulling a tubular bandage over the hand, putting a paper clip on an envelope, and pouring water from a jar into a cup. Range 0-60 seconds for each task. Outcome measure is calculated as: tubular bandage (seconds) x 1.8 + paper clip on an envelope (seconds) + pouring water (seconds) x 1.8
Patient assessment of treatment effect on symptoms
Patient-reported assessment of treatment effect on symptoms (current state compared to before treatment), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of expected treatment effect on symptoms
Patient-reported expectation (reported by the patient prior to treatment) of the treatment's effect on symptoms, reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of CTS symptoms
Patient-reported assessment of CTS-related symptoms (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of CTS-related functional impairment
Patient-reported assessment of current CTS-related functional impairment (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of acceptability of CTS-related symptoms and functional disability
Patient assessment if the current CTS-related symptoms and functional disability are acceptable (yes or no)
Ultrasound measure of proximal cross-sectional area of the median nerve
Bilateral evaluation of the proximal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Ultrasound measure of distal cross-sectional area of the median nerve
Bilateral evaluation of the distal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Ultrasound measures of vascularity of the median nerve in the carpal tunnel
Bilateral evaluation of vascularity of the median nerve in the carpal tunnel. Scored 0 to 3
0: no PD signal
1: 1 singular blood vessel
2: 2-3 single blood vessels or 2 confluent
3: ≥4 single blood vessels or ≥ 3 confluent
Disabilities of the Arm, Shoulder, and Hand (Quick-DASH)
11-item patient reported outcome measure for disabilities of the arm, shoulder, and hand.
(Beaton DE, et al. 2005)
Patient pain assessment
Patient-reported CTS-related pain on a 0-100 mm visual analogue scale (VAS), where 0 indicates no pain and 100 indicates worst possible pain.
Work Productivity and Activity Impairment Questionnaire (WPAI)
Patient-reported outcome of physical function in work and activity. (Reilly MC, et al. 1993)
Days of work absence since start of intervention
Number of days of work absence due to CTS or treatment of CTS since start of intervention
EuroQoL 5-dimension health-related quality of life (EQ5D-5L)
EuroQoL 5-dimension patient-reported outcome for health-related quality of life.
(Herdman M, et al. 2011)
Adverse events
Number and nature of adverse events and serious adverse events
Successful treatment after 1 corticosteroid injection
Only applicable in the injection treatment strategy arm. Subjects who have received 1 corticosteroid injection who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Successful treatment after 2 corticosteroid injections
Only applicable in the injection treatment strategy arm. Subjects who have received 2 corticosteroid injections who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Successful treatment after secondary surgery
Only applicable in the injection treatment strategy arm. Subjects who have received 1 or 2 corticosteroid injections and secondary surgery who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5)
Undergone re-operation
Subject have received a re-operation (yes/no)
A participant who for any reason requires a re-operation, either after primary surgery (surgery arm) or after corticosteroid injection therapy and delayed surgery (injection arm). Reasons for re-operation may, for instance, be wound complications or failure of the initial procedure.
NOTE: Secondary (delayed) surgery in a participant in the injection arm in accordance with the study treatment algorithm is not considered a re-operation.
Cost of treatment
Direct treatment-associated costs, including hospital visits and procedures/interventions. Based on the diagnosis-related group (DRG) pricing system and codified price-lists for medical procedures.